Safety and Pharmacokinetics of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Multiple Dose Escalation Study With a Randomised Phase II Expansion Component
Interventional
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety and tolerability assessed by incidence of adverse events, vital signs, 12-lead ECG, laboratory assessments and physical examination
3 months
Yes
Karim Fizazi
Principal Investigator
Gustave Roussy, Cancer Campus, Grand Paris
United Kingdom: Medicines and Healthcare Products Regulatory Agency
3104001
NCT01317641
March 2011
Name | Location |
---|---|
Cleveland Clinic | Cleveland, Ohio 44195 |
Carolina Urologic Research Center | Myrtle Beach, South Carolina 29572 |
Brooklyn Urology Research Group | Brooklyn, New York 11215 |
The Urology Center of Colorado | Denver, Colorado 80211 |
Delaware Valley Urology, LLC | Mt. Laurel, New Jersey 08054 |
Urology of Virginia, PLLC | Virginia Beach, Virginia 23462 |
Eastern CT Hematology and Oncology Associates | Norwich, Connecticut 06360 |